key: cord-0845924-l9xmj8vi
authors: Kamel, Ahmed M.; Sobhy, Mona; Magdy, Nada; Sabry, Nirmeen; Farid, Samar
title: Anticoagulation outcomes in hospitalized Covid‐19 patients: A systematic review and meta‐analysis of case‐control and cohort studies
date: 2020-10-06
journal: Rev Med Virol
DOI: 10.1002/rmv.2180
sha: 66c7beb7d17cb87350aa740222a579af5a0cee46
doc_id: 845924
cord_uid: l9xmj8vi

Background: Coagulopathy and thromboembolic events are common in Covid‐19 patients and are poor prognostic factors. Controversy exists regarding the potential of anticoagulation (AC) to reduce mortality and incidence of thromboembolic events in Covid‐19 patients. The current systematic review and meta‐analysis investigated the association between anticoagulants and mortality in adult hospitalized COVID‐19 patients using the available published non‐randomized studies. Methods: Google Scholar, PubMed, Scopus, the Cochrane Library and Clinical Trials.gov were searched for relevant studies. A meta‐analysis of adjusted and unadjusted estimates was performed. The relative risk was used as a measure of effect. The random‐effects model was used to pool estimates using the generic inverse variance method. Results: Sixteen studies were included in the quantitative data synthesis. Results showed a statistically significant association between AC and mortality (RR = 0.56, 95% CI 0.36; 0.92, p = 0.02). Both therapeutic (Relative risk [RR] = 0.4, 95% CI 0.27; 0.57) and prophylactic AC (RR = 0.54, 95% CI 0.41; 0.71) were associated with lower risk of mortality. Pre‐admission AC was not associated with mortality (RR = 0.84, 95% CI 0.49; 1.43, p > 0.05) while prophylactic AC was associated with higher risk of mortality compared to therapeutic AC (RR = 1.58, 95% CI 1.34; 1.87, p < 0.001). Conclusion: Findings support the association of AC with mortality in Covid‐19 patients. The results, synthesized from mostly low‐quality studies, show that prophylactic and therapeutic AC might reduce mortality in Covid‐19 patients. Findings suggest that therapeutic doses might be associated with better survival compared to prophylactic doses.

Coronavirus disease 2019 (Covid-19 or SARS-CoV-2), first reported in Wuhan City, is now a global pandemic and is responsible for 4,45,535 deaths globally. 1 Coagulopathy and thromboembolic events are characteristic of Covid-19 and are considered as poor prognostic factors. The respiratory system is the main target of SARS-CoV-2, although other body systems may also be involved. Thus, symptoms might vary from respiratory distress to multiple organ failure. 2 The extent of immune and inflammatory processes disruption is the main determinant of Covid-19 pathogenesis and severity. 3 In severe Covid-19, a storm of overproduced proinflammatory cytokines results in a consequent risk of hypercoagulation, vascular hyperpermeability, multi-organ failure and even death. 4, 5 These findings are supported by the high reported prevalence of venous thromboembolism (VTE), pulmonary embolism (PE) and pulmonary in situ thrombosis. 5, 6 In addition to thromboembolic events, the interplay between coagulation and inflammation has a significant impact on disease progression and can negatively affect the disease management outcomes. 5, 7 Recent evidence suggests that the lung damage caused by SARS-CoV-2 represents a cytokine-storm reaction similar to anaphylaxis. In light of such evidence, the cytokine storm should be given the same priority afforded to traditional cases of anaphylaxis. Randomized clinical trials should also investigate the efficacy of monoclonal antibodies in Covid-19 patients. 8 Different anticoagulants, whether administered orally or parenterally, suppress the synthesis or interfere with the function of clotting factors within the body. 9 Unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), fondaparinux, warfarin, direct thrombin inhibitors and novel oral anticoagulants (NOAC) are anticoagulants with different characteristics targeting the coagulation cascade at different points. 9, 10 Multiple studies investigated the benefit of anticoagulation in Covid-19 patients. In a small retrospective cohort study on 44 Covid-19 patients, using LMWH resulted in higher lymphocyte and lower interleukin-6 levels compared to control patients, indicating an improvement in coagulation parameters and normalization of immunity. 11 In another study, initiation of heparin was associated with improved oxygenation in 27 patients with Covid-19 infection. 12 Controversy exists regarding the dose, timing, risk-benefit ratio and duration of AC in Covid-19 patients. Moreover, the question remains to be answered whether all hospitalized Covid-19 patients would benefit from anticoagulation. The current systematic review and meta-analysis investigated the association between AC and outcomes in hospitalized Covid-19 patients.

The research question for this systematic review was: 'Is the use of therapeutic or/and prophylactic AC associated with mortality and incidence of venous thromboembolism in hospitalized adult Covid-19 patients?' Mortality was defined as death during hospitalization, while venous thromboembolism was defined as deep vein thrombosis (DVT) or/and pulmonary embolism (PE).

The research question (Appendix S2) was broken down and formulated using the Population, Intervention, Control, Outcome and Study criteria framework. 13 Studies were included if they met the following inclusion criteria: (i) Case-control or cohort studies, (ii) hospitalized adult patients with confirmed or suspected Covid-19

and (iii) the use of therapeutic or prophylactic AC. Exclusion criteria were: (i) lack of a control group and (ii) failure to provide information regarding outcomes of anticoagulation in Covid-19 hospitalized patients. No randomized clinical trials were identified when the search was conducted.

A quantitative systematic review in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was performed ( Figure 1 ). 14 Literature search for published studies (prospective or retrospective) was performed. Review articles and articles in non-English language were excluded from the analysis. In-press articles, editorial letters and pre-prints were included in the systematic review if they met the eligibility criteria. All included literature (peer-reviewed, grey literature and non-peer-reviewed material) were subjected to the same rigorous methodological evaluation to ensure consistency. Bibliographies of selected articles and articles citing the selected articles were screened for inclusion. Studies were included even if their primary outcome was not investigating the efficacy of AC. The search was conducted using a combination of controlled vocabulary (MeSH) and title and/or abstract text words. To ensure accuracy, an initial literature review was conducted to identify sentinel articles that should be retrieved when the actual search is performed. Search results from each database were initially exported to Mendeley®, and duplicate citations were identified and discarded. The detailed search strategy (concept maps, keywords and sentinel studies) is described in Appendices S1, S3 and S13, respectively. Two authors (Mona Sobhy and Nada Magdy) independently conducted the searching and identified the eligible studies. Discrepancies were resolved by a third author (Ahmed M. Kamel). 

The risk of bias (RoB) and quality of individually selected studies was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS). 15 The RoB was evaluated based on the ability of the study to investigate the association between AC and mortality using adjusted data. The NOS was developed to assess the quality of non-randomized studies such as cohort and case-control studies (Appendix S2). A 'star system' was developed in which a study is judged on three broad perspectives: the selection of the study groups, the comparability of the groups and the ascertainment of either the exposure or outcome of interest for case-control and cohort studies, respectively.

The quality of each study was graded based on the three F I G U R E 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram of the study selection process for the systematic review and meta-analysis. AC: Anticoagulation KAMEL ET AL.

-3 of 13 abovementioned domains with a maximum possible score of 9. The NOS rating for each study was then converted to the Agency for Healthcare Research and Quality standard. 16 Quality assessment was based on the use of adjusted estimates for the meta-analysis and mortality as the main outcome of interest. For studies that did not provide estimates of mortality, the risk of bias assessment was based on the incidence of VTE (PE, DVT). Well-designed studies that did not primarily adjust the outcome of interest for confounders (using propensity matching or multivariate analysis) were considered of poor quality as per the NOS criteria.

Mortality was the primary outcome in the current meta-analysis.

Secondary outcomes included incidences of PE, DVT and VTE (defined as combined DVT and PE). For studies that reported the effect size for several independent subgroups (e.g., oral and parenteral AC), rather than an overall estimate, the effect size was calculated by pooling either the raw data (e.g., counts) or adjusted estimates across subgroups assuming a correlation of 0. Studies that reported multiple comparisons (e.g., prophylactic AC and therapeutic AC) to the same reference group (no AC) were treated as independent groups when subgroup analysis was performed. That is, the subgroup was used as the unit of analysis. However, these comparisons were pooled (assuming a correlation of 0.5) when looking at the overall effect of AC. In other terms, the study was used as the unit of the analysis. A pooled effect size for VTE was calculated by pooling the results of the individual outcomes (PE and DVT) for studies that did not report an overall incidence of VTE (also assuming a correlation of 0.5, which produces the least biased estimates).

A separate meta-analysis was performed to compare mortality and incidence of VTE between patients who received prophylactic (low or preventive dose) and therapeutic AC (curative, intermediate or full dose) after hospital admission on mortality and incidence of VTE. The analysis was also performed separately for adjusted and unadjusted data.

The analysis was initially performed using the study as the unit of analysis. Effect sizes for various doses of the same anticoagulant within the same study (compared to no AC) were pooled to produce one estimate for each study before pooling the results across studies.

Second, subgroup analysis was performed based on the strength of AC (therapeutic or prophylactic or unknown). The subgroup was used as the unit of analysis in such case. The analysis was performed separately for patients who started AC after admission and patients who were already on anticoagulants at the time of admission (for other indications such as cardiac problems).

Publication bias was evaluated by visual examination of funnel plots.

Egger's regression test was not used to test the asymmetry of the funnel plot due to the small sample size of the included studies. 17 When there was visual evidence of funnel plot asymmetry, potentially missing studies were imputed using the 'trim and fill' method. 18 

Sensitivity (influence) analysis was performed by removing individual studies (based on the risk of bias) and examining the effect size after exclusion to assess the robustness of the results. The pooled estimates were reported for mortality after excluding low and fairquality studies to minimize the risk of bias as recommended by the Cochrane collaboration. 19

The random-effects model (using the Paule-Mandel method as the tau estimator) was used to pool the effect sizes due to the heterogeneity of study populations included in the analysis. 20, 21 The random effect model does not rely on the assumption that a true effect size is the same in all combined studies. The generic inverse variance method was used for weighting.

Relative risk (RR) was used as the unit of effect size for mortality and incidence of VTE. The RR was used because it is more interpretable compared to OR, especially in meta-analysis settings.

The counts and percentages were used to calculate the RR and standard error when available. OR from case-control studies and HR from survival analysis were transformed to RR based on the approximation suggested by VanderWeele. 22 The rare disease assumption was not used when converting OR and HR to RR. Studies with no events in both groups were excluded from the analysis. The total effect (TE) and the corresponding standard error (SeTE) were calculated on natural logarithmic scale (ln) using the following formulas:

Exposure effect estimateðTEÞ ¼ lnðRRÞ SeTE ¼ ln ðUpper confidence limit for RRÞ À lnðLower confidence limit for RRÞ 3:92

Effect sizes were pooled using the generic inverse variance method, and the pooled 95% confidence interval (95% CI) was calculated and used for hypothesis testing. 23 The adjusted estimates were used for the analysis as the RoB assessment was performed based on the adjusted outcomes. However, the analysis was repeated, when data was available, using the unadjusted data, and the results from both analyses were reported. The I 2 was used to assess heterogeneity. The I 2 statistic represents the percentage of variability caused by heterogeneity across studies rather than chance. 24 In cases of moderate to substantial heterogeneity, with I 2 values greater than 50%, we explored and reported the potential causes. The Cochrane Q statistic was used to test the statistical significance of heterogeneity. 24 29 and one reported only the unadjusted estimates for VTE. 30 Quantitative analysis was performed only for estimates of mortality, as less than three studies provided estimates for the incidence of VTE. Thus, the former four studies were excluded from the quantitative analysis.

The systematic review included 19 studies (16 retrospective cohorts and 3 prospective cohorts) and one case-control study. Twelve (60%) studies were of low quality mainly due to comparability issues. Only 3 (15%) and 5 (25%) studies were of fair and good quality, respectively (Table 1 ).

Characteristics of the included studies and patients are included in Appendices S7 and S8, respectively. The outcomes and comparisons extracted from each study are shown in Table 2 . The average/median age was >50 years in 19 studies and was not specified in one study. 31 Covid-19 status was confirmed using real-time polymerase chain reaction in all but one study. 32 Direct oral anticoagulants (DOACs) and warfarin were being used before admission in two studies. 33, 34 Pre-admission anticoagulants were not specified in two studies, [35] [36] [37] while patients were on a variety of anticoagulants prior to admission in one study. 38 UFH and LMWH were the main anticoagulants used in hospitals, although DOAC were also used in some of the included studies. 28, 29, 37, 39 Heparin was used exclusively in one study although the dose was not specified. 40 Only three of the included studies were pre-prints (Appendix S6). A summary of the pooled mortality estimates is shown in Figure 2 . Two studies reported the un-adjusted 30 

Three studies (n ¼ 763) reported adjusted estimates for the association between pre-admission AC and mortality ( Figure 5 ). There was no statistically significant association between pre-admission AC and mortality (RR ¼ 0.84, 95% CI 0.49; 1.43, p > 0.05). The influence analysis did not alter the pooled estimate ( Figure S8 ). One study was of good quality 35 while the remaining two were of poor quality. 33 Figure S11) . Four of the studies described the pre-admission AC as therapeutic. 33 Note: Studies that provided information for more than one comparison were reported more than once based on the number of comparisons.

Abbreviations: AC, anticoagulation; DOAC, direct oral anticoagulants; DVT, deep venous thrombosis; LMWH, low molecular weight heparin; NOAC, novel oral anticoagulants; PE, pulmonary embolism; VKA, vitamin K antagonist; VTE, venous thromboembolism. a Studies that provided data to compare therapeutic and prophylactic AC. b Not included in the meta-analysis.

Summary of mortality pooled estimates in the current systematic review. AC, anticoagulation; CI, confidence interval; E1, exposure 1; E2, exposure 2; RR, risk ratio; SeTE, standard error; TE, total effect F I G U R E 3 Random-effects model for the association between in-hospital AC and mortality. AC, Anticoagulation; CI, confidence interval; RR, risk ratio; SeTE, standard error; TE, total effect

Three studies (n ¼ 869) provided the adjusted estimates for mortality in patients who received low and high doses of anticoagulants 41, 42, 44 while four studies 41, 42, 44, 45 provided unadjusted estimates (n ¼ 895).

The pooled estimate for mortality ( Figure 6 ) favoured therapeutic AC when the adjusted estimates were used for the analysis (RR ¼ 1.58, 95% CI 1.34; 1.87, p < 0.001), and no heterogeneity was observed between studies (I 2 ¼ 0%). The estimate was robust to the leave-oneout sensitivity analysis ( Figure S12 ). Pooled analysis of unadjusted estimates ( Figure S13 ), on the other hand, was not statistically sig- The association between AC and the incidence of VTE was reported in two studies. 32, 45 The association between AC and incidence of PE and DVT was reported in one study each. 28, 29 Meta-analysis was not performed for these estimates due to the small number of studies.

Based on evidence from a recently published meta-analysis, the pooled estimate for mortality during an average follow-up of 17.5 days was 6.6% (95% 2.8%; 15%). The pooled estimates for the incidence of VTE were 30.3% and 13.4% in ICU and ward settings, while the incidence of PE was estimated at 15.7% and 5.6%, respectively. 46 Preliminary data showed that prophylactic anti-coagulation is associated with lower mortality in Covid-19 patients, especially in patients with elevated levels of D-dimer and who are on mechanical ventilation. 31, 43 Therapeutic, prophylactic and pre-admission anticoagulation were also associated with a lower risk of pulmonary embolism. 29 Zhang reported a beneficial effect for AC in patients with Padua risk score ≥4, although it was not statistically significant. 27 Tang et al. 43 not associated with mortality using a competing risk model. 36 The estimate, in the current meta-analysis, was robust when the unadjusted estimates were used. This might shed some light on the true estimate of the association between these factors and the confounding introduced by the research question itself.

To the best of our knowledge, this is the first meta-analysis to investigate, separately, the effect of pre-admission and in hospital AC on mortality and incidence of VTE using only case-control and cohort studies. This might reduce the bias that may result from including all AC settings in one meta-analysis as patients who were initiated on anticoagulants before admission are more likely to do so for various comorbidities that might influence the reported outcomes.

The current systematic review and meta-analysis also investigated the effect of high versus low dose AC and showed that prophylactic AC might be associated with higher mortality than therapeutic AC. The results were derived from only three studies that provided the adjusted estimates. The benefit of therapeutic AC must be weighed against various adverse outcomes associated with anticoagulants' use, specifically bleeding, which is the major adverse effect of concern. 9,10 Bleeding cannot be neglected as an adverse effect of AC, especially in the presence of thrombocytopenia status in Covid-19 infected patients associated with infection severity and mortality. 53 Additionally, reported cases of bleeding were investigated in patients with Covid-19 infection. 54, 55 Findings regarding the 10 of 13association between the dose of the used anticoagulant and mortality are also inconclusive as the unadjusted estimates yielded different results and, thus, should be interpreted with caution.

More than half of the included studies were of low-quality, which is reflected by the NOS tool. Although the adjusted estimates were used for the primary analysis, selection bias and confounding can influence the reported results due to the non-randomized and mostly retrospective nature of the included studies. Moreover, some studies did not specify the dose 40 of the used anticoagulants, and some studies were restricted to specific subgroups such as patients on mechanical ventilation who might not be representative of hospitalized Covid-19 patients. 35, 44 Various anticoagulants and doses were used across studies, and some studies did not report the exact doses used. Moreover, the pooled estimates were not calculated for VTE

due to the small sample size.

The current systematic review and meta-analysis, which included only controlled non-randomized studies, provide evidence to support the association of AC with mortality in Covid-19 patients. The results, synthesized from mostly low-quality studies, show that prophylactic AC may reduce mortality in Covid-19 patients. They also show that therapeutic AC might offer an advantage over prophylactic AC. Randomized clinical trials are highly encouraged to produce high-quality evidence regarding the safety and efficacy of AC.

COVID-19): situation report, 51. World Health Organization

COVID-19 pathophysiology: a review

A glimpse into the eye of the COVID-19 cytokine storm

Inflammatory cytokines in the BAL of patients with ARDS

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Covid-19: Time for a paradigm change

Anticoagulation drug therapy: a review

Anticoagulants: a review of the pharmacology, dosing, and complications

The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study. medRxiv

Heparin therapy improving hypoxia in COVID-19 patients -a case series

Utilization of the PICO framework to improve searching PubMed for clinical questions

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses

Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Methods Guide for Effectiveness and Comparative Effectiveness Reviews

Agency for

A comparison of methods to detect publication bias in meta-analysis

trim and fill" method of accounting for publication bias in meta-analysis

Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies

Meta-analysis in clinical trials

Methods to estimate the between-study variance and its uncertainty in meta-analysis

Optimal approximate conversions of odds ratios and hazard ratios to risk ratios

Introduction to Meta-Analysis

Quantifying heterogeneity in a meta-analysis

Comprehensive Meta-Analysis Version 3

R: A Language and Environment for Statistical Computing

Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevalence, risk factors, and outcome. Circulation

Clinical characteristics of acute lower extremity deep venous thrombosis diagnosed by duplex in patients hospitalized for coronavirus disease (COVID-19)

Pulmonary embolism in COVID-19 patients: a French multicentre cohort study

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19

Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study

Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study

Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era

Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis

30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study

COVID-19 mortality in patients on anticoagulants and antiplatelet agents

Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship to anticoagulation status

The association between treatment with heparin and survival in patients with Covid-19

ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19

Low molecular weight heparin in adults inpatient COVID-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated COVID-19 patients. medRxiv

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis

The role of anticoagulation in COVID-19-induced hypercoagulability

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?

Thrombolysis restores perfusion in COVID-19 hypoxia

Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic

COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a metaanalysis

Heparin-related major bleeding in covid-19-positive patient: perspective from the outbreak

Bleeding in COVID-19 severe pneumonia: the other side of abnormal coagulation pattern?

SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of this article

Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies

We would like to thank Dr. Helena Sivaloganathan for providing essential data for the analysis. This research did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare that they have no conflict of interest. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0002-3791-5998